Regeneron Pharmaceuticals total non-operating income/expense for the twelve months ending December 31, 2024 was $0.789B, a 418.53% increase year-over-year.
Regeneron Pharmaceuticals annual total non-operating income/expense for 2024 was $0.789B, a 418.53% increase from 2023.
Regeneron Pharmaceuticals annual total non-operating income/expense for 2023 was $0.152B, a 26.94% increase from 2022.
Regeneron Pharmaceuticals annual total non-operating income/expense for 2022 was $0.12B, a 68.36% decline from 2021.
Regeneron Pharmaceuticals Total Non-Operating Income/Expense 2010-2024 | REGN